Swiss pharmaceutical lab company Novartis announced its 8th R&D centre in Shanghaï, China.
Mainly dedicated to research on infectious causes of prevalent cancers in China, this centre represents a USD 100 million investment. By establishing its new centre, which should employ more than 400 researchers by 2008, at the Zhangjiang Hi-Tech Park, near Shanghaï, Novartis bets on the development of this emerging life science cluster.